Moreover, despite the absence of amplifications, the existence of ERBB2 mutations and increased protein levels, indicate that ERBB2 inhibitors may be an alternative therapeutic approach for LAR subtype tumours [19]. The gene discussed is ERBB2; the disease is neoplasm.